An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD.

Autor: Inamoto Y; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.; Department of Blood and Marrow Transplantation and Cellular Therapy, Fujita Health University, Toyoake, Japan., Kato K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan., Kawakita T; Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan., Onishi Y; Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan., Matsuoka KI; Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Shiratori S; Department of Hematology, Hokkaido University Faculty of Medicine, Hokkaido, Japan., Ikegame K; Department of Hematology, Hyogo Medical University Hospital, Hyogo, Japan., Hiramoto N; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan., Toyosaki M; Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan., Katayama Y; Department of Hematology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan., Murayama S; Meiji Seika Pharma Co., Ltd., Tokyo, Japan., Sasagawa Y; Meiji Seika Pharma Co., Ltd., Tokyo, Japan., Maeda Y; Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Hatake K; Department of Hematology, Akasaka Sanno Medical Center, Tokyo, Japan.; School of Medicine, International University of Health and Welfare, Tokyo, Japan., Teshima T; Department of Hematology, Hokkaido University Faculty of Medicine, Hokkaido, Japan.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Oct; Vol. 99 (10), pp. 1917-1926. Date of Electronic Publication: 2024 Jun 27.

Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan.

Autor: Kawasaki A; Ono Pharmaceutical Co., Ltd, 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan. ak.kawasaki@ono-pharma.com., Hatake K; Department of Hematology, International University of Health and Welfare, Tokyo, Japan., Matsumura I; Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan., Izutsu K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan., Hoshino T; Ono Pharmaceutical Co., Ltd, 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan., Akamatsu A; Ono Pharmaceutical Co., Ltd, 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan., Kakuuchi A; Ono Pharmaceutical Co., Ltd, 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan., Tobinai K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Publikováno v: International journal of hematology [Int J Hematol] 2024 Jun; Vol. 119 (6), pp. 667-676. Date of Electronic Publication: 2024 Mar 23.

Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy

Autor: Kodaira, M., Takahashi, S. ^*, Yamada, S., Ueda, K., Mishima, Y., Takeuchi, K., Yamamoto, N., Ishikawa, Y., Yokoyama, M., Saotome, T., Terui, Y., Hatake, K.

Publikováno v: In Annals of Oncology June 2010 21(6):1163-1167

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

Autor: Ennishi, D., Takeuchi, K., Yokoyama, M., Asai, H., Mishima, Y., Terui, Y., Takahashi, S., Komatsu, H., Ikeda, K., Yamaguchi, M., Suzuki, R., Tanimoto, M., Hatake, K. ^*

Publikováno v: In Annals of Oncology November 2008 19(11):1921-1926

A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.

Autor: Kato K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Fukuoka Higashi-ku, Fukuoka, 812-8582, Japan. kato.koji.429@m.kyushu-u.ac.jp., Fujii N; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan., Makita S; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan., Goto H; Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan., Kanda J; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Shimada K; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Akashi K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Fukuoka Higashi-ku, Fukuoka, 812-8582, Japan., Izutsu K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan., Teshima T; Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan., Fukuda N; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Sumitani T; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Nakamura S; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Sumi H; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Shimizu S; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Kakurai Y; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Yoshikawa K; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Tobinai K; Geriatric Health Services Facility Rehabilitation Care Funabashi, Chiba, Japan., Usui N; Department of Clinical Oncology and Hematology, The Jikei University Daisan Hospital, Tokyo, Japan., Hatake K; Department of Lymphoma/Hematology Center, Mita Hospital, International University of Health and Welfare, Tokyo, Japan.

Publikováno v: International journal of hematology [Int J Hematol] 2023 Mar; Vol. 117 (3), pp. 409-420. Date of Electronic Publication: 2022 Nov 18.